The 40-Amino-Acid Line
The 40-Amino-Acid Line: The Number That Shapes the Peptide Market
One amino acid decides whether a molecule is a cheap generic or a billion-dollar biologic. Forty is a drug. Forty-one is not.
The last article ended on size. How big a molecule is determines whether it can cross your gut wall, pass through your skin, or fit through the only transporter available to it.
Size determines something else too, and this one is stranger: a molecule's legal identity.
There is a specific number in US regulation where a peptide stops being one kind of thing and becomes another. Cross it and the approval pathway changes, the exclusivity period more than doubles, cheap generic copies become impossible, and compounding pharmacies lose the ability to touch it.
The number is 40.
A molecule of 40 amino acids or fewer fits the FDA's working definition of a peptide. Above that, it falls within the definition of a protein. That distinction is a major factor in which regulatory pathway applies — though it doesn't single-handedly decide the outcome, and it's a regulatory line, not a biological one. The chemistry is the same on both sides.
What actually changes at the line
Four things, and each one matters more than it sounds.
The application changes. Below the line you file a New Drug Application. Above it, a Biologics License Application — a different law, a different review division, a different evidence package.
Copies become a different problem entirely. This is the big one.
Exclusivity roughly doubles. A new drug gets five years of protection from the regulator, on top of whatever patents apply. A new biologic gets twelve from first licensure.
Compounding access largely closes. More on this shortly — it's the row with the most practical consequence for anyone reading about peptides online.
Insulin, and the day the category changed
The cleanest illustration is insulin, because it changed sides while everyone watched.
Insulin is 51 amino acids across two chains. It's been in clinical use for a century, and for most of that time it was regulated in the US as a drug.
That ended in March 2020, when a long-scheduled provision took effect and insulin — along with human growth hormone and several other products — was formally reclassified as a biologic. The molecules didn't change. The category did.
The intent was to open a biosimilar pathway for insulin and bring prices down. The point for our purposes is simpler: insulin is 51 amino acids, comfortably above the line, so it belongs on the biologic side.
Now compare:
| Molecule | Amino acids | Category |
|---|---|---|
| Octreotide | 8 | Drug |
| Semaglutide | 31 | Drug |
| Teriparatide | 34 | Drug |
| Tirzepatide | 39 | Drug |
| Insulin | 51 | Biologic |
| Human growth hormone | 191 | Biologic |
Look at tirzepatide. Thirty-nine amino acids. One residue below the line.
The row that matters most: compounding
If you've spent any time reading about peptides online, you've encountered compounded products. This is where the 40 rule stops being abstract.
That last point is the mechanism. A compounding pharmacy can't use just any substance. The starting material generally has to be one of: an ingredient in an already-approved drug, a substance with an official quality monograph, or a substance the FDA has specifically placed on a permitted list.
Two consequences follow directly.
First, biologics are effectively out. Their ingredients don't clear those requirements, and the manufacturing standards are a different world. If a molecule is over 40 amino acids, compounding is largely not an available route — which is a large part of why compounded peptide offerings cluster below the line.
Second, the FDA actively reviews individual peptides and can remove them from eligibility. In 2023 the agency evaluated a set of peptide substances that had been circulating in compounding and placed a number of them in a category reserved for substances raising significant safety concerns — which removes them from the permitted pathway. BPC-157 was among the most widely reported. The list is reviewed and updated, so its current contents are worth checking rather than assuming.
And the semaglutide case shows how conditional this all is. During the GLP-1 shortage, compounded semaglutide became widely available — legal specifically because the drug was on the shortage list, which opens a temporary route. When FDA declared the shortage resolved, that route closed, with a wind-down period. The pharmacies didn't change. The conditions did.
There was a second problem running alongside it. Some compounded products used semaglutide salt forms — semaglutide sodium, semaglutide acetate — which the FDA flagged as not being the same active ingredient as the approved drug. Different chemical entity, sold under the same name.
Which should sound familiar. It's the Article 1 problem wearing a regulatory costume.
Why designers watch the number
Pharmacology drives molecular design. But the line at 40 sits in the background as a real pressure, and it explains some structures better than pharmacology alone does.
Natural parathyroid hormone is 84 amino acids. The approved osteoporosis drug teriparatide is the first 34 — a fragment that carries the receptor-activating portion. There's a solid biological argument for that truncation. There's also the fact that 34 lands on the drug side of the line and 84 doesn't.
Tirzepatide at 39 is the more striking case. Whatever combination of reasons produced that length, the result is a molecule that sits one residue inside the drug category — with a synthesis-based supply chain, a New Drug Application pathway (an NDA, the approval route used for drugs rather than biologics), and eventual generic potential that a 41-residue version would not have.
The molecules you see on the market are shaped by this. Not entirely, and not always deliberately. But enough that the shape of the market makes more sense once you know the number is there.
What this gives you
Three things you can now do.
Predict the copy landscape. Under 40, expect generics eventually and a real price drop. Over 40, expect biosimilars at best, and a much smaller one.
Understand why compounded peptides cluster where they do. It isn't arbitrary. It's the direct output of ingredient eligibility rules and the 40-residue boundary.
Hear "compounded" correctly. It's a legal category with conditions attached — conditions that can and do change, sometimes quickly.
Next, we look at how one of these molecules actually gets engineered. Liraglutide is a daily injection. Semaglutide is weekly. Same target, same class, and the gap between them took three separate modifications — each of which would have been useless without the other two.
This article is educational and not medical advice. It describes US regulatory categories in general terms and is not a guide to compliance. Rules and permitted-substance lists change; verify current status before relying on anything here. Decisions about any therapy belong with a qualified clinician who knows your history.